RKM4 Antibody

What is RBM4 and why is it important in research?

RBM4 belongs to the RNA recognition motif (RRM)-containing protein family and functions as a critical post-transcriptional regulator. It contains two RNA recognition motifs and a CCHC-type zinc finger domain that mediate its interaction with target RNAs. RBM4 participates in multiple cellular processes including alternative splicing regulation, translation control during cell stress, and miRNA-mediated gene silencing. Due to its diverse roles in RNA metabolism, RBM4 has become an important research target in fields ranging from developmental biology to cancer research. When selecting antibodies against RBM4, researchers should consider the specific applications and epitope recognition requirements based on their experimental design, similar to considerations for other RNA-binding proteins studied with antibodies .

What types of RBM4 antibodies are available for research?

RBM4 antibodies are available in several formats, similar to other research antibodies:

Proteintech offers a polyclonal RBM4 antibody (11614-1-AP) that researchers can use for various applications . When selecting antibodies, researchers should consider validation data similar to those provided for other antibodies like BRD4 antibody, which includes western blot confirmation of predicted band size and immunohistochemistry results .

What applications are RBM4 antibodies validated for?

RBM4 antibodies can be used in multiple experimental contexts:

• Western blotting: For detecting RBM4 protein expression levels

• Immunoprecipitation (IP): For studying RBM4 protein interactions

• Immunofluorescence (IF): For visualizing subcellular localization

• Immunohistochemistry (IHC): For tissue expression analysis

• RNA immunoprecipitation (RIP): For identifying RBM4-bound RNAs

When selecting antibodies for specific applications, researchers should verify validation data similar to that shown for other antibodies, which typically include confirmation of predicted molecular weight bands in western blot (as seen with BRD4 antibody showing the expected 152 kDa band) .

How should I validate RBM4 antibody specificity for my experiments?

Proper validation of RBM4 antibody specificity is critical for obtaining reliable results:

• Molecular weight verification: Confirm that western blot results show the expected molecular weight band (approximately 40 kDa for RBM4)

• Positive and negative controls: Include tissues/cells known to express or lack RBM4

• Knockdown/knockout validation: Test antibody on samples where RBM4 has been depleted using siRNA or CRISPR to confirm signal reduction

• Cross-validation: Compare results across different antibody clones targeting different RBM4 epitopes

• Computational prediction: Use biophysics-informed modeling to assess potential cross-reactivity, similar to approaches described for designing antibody specificity

Recent advances in antibody design have demonstrated that computational models can help predict binding specificity by identifying different binding modes associated with particular ligands, which could be applied to validate RBM4 antibody specificity .

What are the optimal conditions for Western blotting with RBM4 antibodies?

Optimizing Western blot conditions for RBM4 detection requires attention to several parameters:

These conditions should be optimized for each specific RBM4 antibody, following principles similar to those described for other antibodies like BRD4, where blocking with 5% NFDM/TBST has been validated .

How do I optimize immunofluorescence staining with RBM4 antibodies?

For high-quality immunofluorescence results when studying RBM4:

• Fixation: 4% paraformaldehyde (10-15 minutes) preserves protein structure while maintaining epitope accessibility. For certain epitopes, methanol fixation may yield better results.

• Permeabilization: 0.1-0.3% Triton X-100 in PBS (10 minutes) allows antibody access to intracellular RBM4.

• Blocking: 5-10% normal serum (from the same species as secondary antibody) with 1% BSA (1 hour) minimizes non-specific binding.

• Antibody dilution: Start with 1:100-1:500 for primary antibody and 1:500-1:1000 for fluorophore-conjugated secondary antibody.

• Counterstaining: DAPI (1:1000) for nuclear visualization, as RBM4 often shows nuclear or nucleocytoplasmic localization.

• Controls: Include secondary-only controls to assess background, as demonstrated in BRD4 antibody validation images .

For co-localization studies, select fluorophores with minimal spectral overlap and include single-staining controls to assess bleed-through, following principles similar to those shown in P4A2 antibody immunofluorescence studies .

How can I use RBM4 antibodies to study protein-RNA interactions?

RBM4 antibodies are valuable tools for investigating RBM4-RNA interactions through several techniques:

• RNA Immunoprecipitation (RIP):

  • Cross-link protein-RNA complexes with formaldehyde or UV

  • Lyse cells in non-denaturing conditions

  • Immunoprecipitate with RBM4 antibody (5-10 μg per sample)

  • Extract and analyze RNA by qRT-PCR or sequencing

  • Include IgG control to identify non-specific binding

• Cross-Linking Immunoprecipitation (CLIP):

  • UV cross-linking creates covalent bonds between proteins and directly bound RNAs

  • RBM4 antibody precipitation followed by partial RNA digestion

  • Adapter ligation and high-throughput sequencing reveal binding sites with nucleotide resolution

  • Requires high-specificity antibodies that perform well in immunoprecipitation

• Proximity-Based RNA Labeling:

  • Express RBM4 fused to RNA-modifying enzymes

  • Validate fusion protein recognition by RBM4 antibody

  • Map RNA-protein interactions in living cells

These approaches build on established immunoprecipitation principles similar to those used with other antibodies, where selecting antibodies validated for IP applications is critical for success .

What approaches can reveal RBM4's role in alternative splicing?

To investigate RBM4's function in alternative splicing regulation:

• Splicing-Sensitive RT-PCR:

  • Manipulate RBM4 levels (overexpression or knockdown)

  • Design primers spanning alternatively spliced exons

  • Validate RBM4 expression changes by western blot with RBM4 antibody

  • Quantify isoform ratios by RT-PCR

• RNA-Seq with RBM4 Perturbation:

  • Manipulate RBM4 expression (siRNA, CRISPR, overexpression)

  • Confirm changes with RBM4 antibody by western blot

  • Perform RNA-seq and analyze with splicing-aware tools (rMATS, VAST-TOOLS)

  • Validate key targets with RT-PCR and qPCR

• RBM4 Binding Correlation with Splicing Outcomes:

  • Map RBM4 binding sites using CLIP-seq with RBM4 antibody

  • Correlate binding patterns with splicing changes

  • Perform minigene assays to confirm direct regulation

These approaches adapt methodologies similar to those used in antibody-dependent experiments for other RNA-binding proteins, where careful validation of antibody specificity is essential .

How can I analyze RBM4 expression in different subcellular compartments?

RBM4 shuttles between nucleus and cytoplasm, making subcellular localization analysis important:

• Subcellular Fractionation with Western Blotting:

  • Separate nuclear, cytoplasmic, and other fractions using differential centrifugation

  • Confirm fraction purity with compartment-specific markers

  • Analyze RBM4 distribution by western blot with RBM4 antibody

  • Quantify relative distribution across compartments

• Immunofluorescence for Spatial Resolution:

  • Use optimized immunofluorescence protocol (see 2.3)

  • Counterstain with compartment markers (e.g., DAPI for nucleus)

  • Perform confocal microscopy for high-resolution imaging

  • Analyze co-localization using appropriate software

• Stimulation-Dependent Relocalization:

  • Treat cells with stressors (e.g., arsenite, thapsigargin)

  • Track RBM4 relocalization using immunofluorescence

  • Perform time-course analysis of redistribution

  • Correlate with functional outcomes (e.g., translation regulation)

Similar approaches have been successfully used with other antibodies to track protein localization during cellular stress or infection, as demonstrated with P4A2 antibody in SARS-CoV-2 infected cells .

Why might I observe multiple bands in Western blots with RBM4 antibody?

Multiple bands in RBM4 western blots can result from several factors:

• Isoforms: RBM4 has multiple splice variants (RBM4A and RBM4B) with slightly different molecular weights

• Post-translational modifications:

  • Phosphorylation increases apparent molecular weight by 1-2 kDa

  • RBM4 is phosphorylated during cell stress, potentially creating band shifts

• Proteolytic degradation: Sample preparation without proper protease inhibitors may result in degradation products

• Cross-reactivity: Antibody may recognize related proteins, especially other RRM-containing proteins

• Non-specific binding: Insufficient blocking or high antibody concentration can cause non-specific binding

To differentiate true signal from artifacts:

• Use positive controls from tissues with known RBM4 expression

• Include RBM4 knockdown/knockout samples

• Compare multiple RBM4 antibodies targeting different epitopes

• Adjust blocking conditions and antibody concentration

These troubleshooting approaches follow general principles used for other antibodies, where careful validation is required to confirm observed bands represent the target protein .

How can I minimize background in immunohistochemistry with RBM4 antibodies?

High background in RBM4 immunohistochemistry can be addressed through systematic optimization:

For optimal results, heat-mediated antigen retrieval methods like those described for BRD4 antibody immunohistochemistry should be tested, where BOND Polymer Refine Detection kits with heat-mediated antigen retrieval using Tris-EDTA buffer (pH 9.0) for 20 minutes have been successful .

How do I resolve inconsistent RBM4 staining patterns across different samples?

Inconsistent RBM4 staining may result from technical or biological factors:

Technical factors:

• Fixation variability: Standardize fixation time and conditions (4% PFA, 24-48 hours for tissues)

• Antigen retrieval: Ensure consistent temperature, duration, and pH of retrieval solution

• Antibody penetration: For thick sections, increase incubation times or use detergent

• Batch effects: Process all samples simultaneously when possible

• Storage conditions: Minimize section storage time before staining

Biological factors:

• Developmental regulation: RBM4 expression varies across developmental stages

• Stress response: Cellular stress alters RBM4 localization and expression

• Tissue-specific isoforms: Different tissues may express different RBM4 isoforms

• Post-translational modifications: Modifications may mask epitopes in specific contexts

To address inconsistency, implement positive controls (tissues known to express RBM4) and standardize all protocol steps. Including appropriate controls is critical, similar to the approach shown in BRD4 immunohistochemistry validation where control images demonstrate absence of staining in secondary antibody-only controls .

How can I quantitatively analyze RBM4 protein levels across experimental conditions?

Quantitative analysis of RBM4 requires rigorous methodology:

• Quantitative Western Blotting:

  • Include standard curve with recombinant RBM4 protein

  • Use fluorescence-based detection for wider linear range

  • Normalize to total protein stain rather than single housekeeping proteins

  • Use image analysis software with background subtraction

  • Report results as fold-change relative to control samples

• Quantitative Immunofluorescence:

  • Standardize image acquisition parameters (exposure, gain)

  • Include fluorescence standards for calibration

  • Perform automated image analysis with defined thresholds

  • Report intensity as integrated density or mean fluorescence

  • Analyze sufficient cell numbers for statistical power

• Flow Cytometry for Single-Cell Analysis:

  • Optimize fixation and permeabilization for intracellular staining

  • Include fluorescence-minus-one controls

  • Gate on specific cell populations if analyzing heterogeneous samples

  • Measure median fluorescence intensity rather than mean

  • Present data as histograms and quantitative comparisons

These approaches follow quantitative principles similar to those used for other intracellular proteins, such as the flow cytometry analysis methods demonstrated for BRD4 antibody validation in SW480 cells .

What considerations apply when using RBM4 antibodies for cross-species research?

When using RBM4 antibodies across different species:

• Epitope conservation assessment:

  • Align RBM4 sequences from target species

  • Identify regions of high conservation

  • Select antibodies targeting conserved epitopes

  • Validate empirically in each species

• Species-specific validation:

  • Test antibody on tissues from each species

  • Include positive and negative controls

  • Consider epitope-specific modifications in different species

  • Optimize protocol for each species independently

• Alternative approaches for non-validated species:

  • Generate species-specific antibodies if necessary

  • Consider using tagged RBM4 in experimental systems

  • Validate results with orthogonal methods

Cross-species applications require careful validation similar to approaches used in developing broadly neutralizing antibodies, where understanding epitope conservation is crucial for predicting cross-reactivity .

How can computational approaches enhance RBM4 antibody specificity analysis?

Advanced computational methods can improve RBM4 antibody specificity:

• Epitope prediction and analysis:

  • Use algorithms to predict RBM4 surface-exposed epitopes

  • Model antibody-epitope interactions

  • Identify potential cross-reactive proteins with similar epitopes

• Binding mode analysis:

  • Implement biophysics-informed modeling to identify different binding modes

  • Disentangle binding specificities for closely related epitopes

  • Design specific antibodies based on computational predictions

• Machine learning for specificity optimization:

  • Train models on high-throughput antibody characterization data

  • Predict specificity profiles for new antibody candidates

  • Guide experimental validation of most promising candidates

These computational approaches align with advanced methods described for antibody design and specificity engineering, where models can successfully predict binding behavior and guide the design of antibodies with customized specificity profiles .